Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Survodutide peptide icon, one bubble per amino acidSurvodutide29 residuesHXQGTFTSDYSKYLDERAAKDFIKWLESAEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Survodutide

Beginner tier: 600 mcg, weekly · clinical trials

~6 days half-life·Injection

Also known as: BI 456906, BI-456906

62% of MASH patients improved in 48 weeks without their fibrosis getting worse. That result, from a 2024 NEJM trial of 293 patients, put survodutide on the map as a dual GLP-1/glucagon receptor agonist built for metabolic liver disease. Boehringer Ingelheim's Phase 3 obesity trials (SYNCHRONIZE-1 and -2) reported 9.8 to 13.0% weight loss on 6.0 mg at 76 weeks in 2026. The compound also produced 18.7% body weight loss at 46 weeks in a separate Phase 2 obesity trial. It isn't FDA-approved, and the 40-week dose escalation schedule is slow by any standard. For people tracking MASH therapies or next-generation weight loss agents, survodutide is one to watch closely.

What Is Survodutide?

62% of MASH patients improved in under a year, without their fibrosis getting worse. That's the headline number from the Phase 2 MASH trial published in the New England Journal of Medicine (n=293)[1]. Survodutide (BI 456906) is a dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim. It works two angles at once: GLP-1 receptor activation suppresses appetite and slows gastric emptying, while glucagon receptor activation drives hepatic fat oxidation and thermogenesis. Compared to semaglutide and tirzepatide, survodutide adds the glucagon receptor arm those two lack, which is why its early data centers on liver fat.

The MASH trial at 4.8 mg weekly showed 62% of participants improved in MASH without worsening of fibrosis at 48 weeks, versus 14% on placebo. Fibrosis improved by at least one stage in 36%, and liver fat dropped by at least 30% in 67% of participants. A separate Phase 2 obesity trial (Lancet 2024, n=387)[2] landed on 18.7% weight loss at 46 weeks with the same 4.8 mg dose.

Phase 3 obesity results landed in 2026. SYNCHRONIZE-1 (NCT06066515) enrolled adults without diabetes. At 76 weeks, 3.6 and 6.0 mg produced 12.2% and 13.0% weight loss vs 5.4% on placebo (NEJM 2026)[4]. SYNCHRONIZE-2 (NCT06066528, n=752) enrolled adults with obesity and type 2 diabetes, who lost 8.2% and 9.8% vs 3.9% (NEJM 2026)[5]. Both counted everyone randomized. Neither is a MASH trial; the MASH Phase 3, LIVERAGE (NCT06632444), is still recruiting.

One wrinkle worth knowing: Phase 2 turned up a non-linear dose response for MASH. The 6.0 mg arm actually had worse MASH improvement than 4.8 mg (43% vs 62%). Whether that pattern holds in Phase 3 will matter. The compound is not FDA-approved, not commercially available, and carries the usual GLP-1 class GI burden. About 75% of Phase 2 participants reported gastrointestinal side effects.

How Survodutide Works

Survodutide activates two receptors that complement each other. GLP-1 receptor agonism suppresses appetite through hypothalamic signaling, slows gastric emptying (which extends satiety), and boosts glucose-dependent insulin secretion. That side of the molecule handles the appetite and blood sugar piece.

The glucagon receptor component does something GLP-1-only drugs cannot. Glucagon receptor activation increases hepatic fat oxidation, converting stored liver fat into energy. It also raises energy expenditure through thermogenesis and promotes lipolysis in adipose tissue. This is the mechanism behind the dramatic liver fat reduction in the MASH trial.

A C18 diacid modification on the peptide enables albumin binding in the bloodstream. That extends the half-life to approximately 6 days, making weekly subcutaneous dosing practical. The dual-receptor approach creates a built-in counterbalance: GLP-1 lowers blood glucose while glucagon tends to raise it. In clinical trials, the net effect on fasting glucose was neutral to mildly favorable in non-diabetic participants, with no significant hypoglycemia reported.

Survodutide Benefits

  • Survodutide benefits center on liver fat reduction and metabolic weight loss through its dual GLP-1/glucagon mechanism.
  • 62% of MASH patients improved in MASH without worsening of fibrosis at 4.8 mg weekly, and 67% had at least a 30% drop in liver fat (NEJM 2024, n=293)[1].
  • 18.7% mean body weight loss at 46 weeks (4.8 mg, actual-treatment analysis) in the Phase 2 obesity trial, with 55% of participants losing 15% or more (Lancet 2024)[2].
  • 36% of the 4.8 mg group improved fibrosis by at least one stage without worsening MASH in Phase 2, versus 22% on placebo; among the strongest published fibrosis data for a dual agonist.
  • Weekly dosing from a single subcutaneous injection, enabled by C18 diacid albumin-binding modification with a half-life of approximately 6 days.
  • Glucagon receptor-driven thermogenesis adds an energy expenditure component that pure GLP-1 agonists lack; this may explain the particularly strong liver fat results.

Survodutide: Science vs Community Consensus

Science Only
Scientific Evidence
Moderate
Based on 8 key studies·Phase 3

Phase 2 data supports meaningful weight loss (up to 18.7% at 46 weeks) and MASH improvement (62% improved without worsening fibrosis, 67% with at least a 30% liver fat reduction at 48 weeks) at 4.8mg weekly.

Dosing studied: 3.6–6.0mg/week (Phase 3 target doses); 4.8mg/week is the best Phase 2 evidence base
Read the evidence (key study, limitations)

Phase 3 at 3.6mg and 6.0mg confirmed weight loss at 76 weeks (treatment-regimen estimand). SYNCHRONIZE-1 found 12.2 to 13.0% without diabetes; SYNCHRONIZE-2 found 8.2 to 9.8% with type 2 diabetes.

Key Study

Phase 2 MASH trial: NEJM 2024 (PMID 38847460): at 4.8mg over 48 weeks, 62% improved in MASH without worsening of fibrosis vs 14% placebo, 36% improved fibrosis by at least one stage, and 67% had at least a 30% reduction in liver fat. Phase 2 obesity trial: Lancet 2024 (PMID 38330987): 18.7% weight loss at 46 weeks at 4.8mg vs. 2.3% placebo.

Limitations

No Phase 3 MASH biopsy results yet (LIVERAGE is recruiting). Phase 2 MASH trial had non-linear dose-response: 4.8mg outperformed 6.0mg for improvement in MASH (62% vs 43%). Long-term safety >48 weeks uncharacterized. Not FDA-approved.

Community Experience
Weak
4.0/5
Based on ~100–200 Reddit threads

Very limited self-experimentation; most community discussion is about trial data, not personal reports.

Community dosing: Mirrors clinical titration: slow escalation from 0.3mg to 4.8mg weekly over 40+ weeks
Read the reports (what users report 4, common issues 5)

Discussed as a future leading MASH + obesity agent. Less accessible than tirzepatide or retatrutide in grey market.

What users report (4)
  • Best-in-class liver fat data among investigational agents (67% of the 4.8mg group cut liver fat by at least 30% in Phase 2)
  • Strong body weight loss at 4.8mg (18.7% in the actual-treatment analysis; 14.9% planned-treatment mITT)
  • Weekly dosing; Boehringer Ingelheim backing increases confidence in future availability
  • Glucagon component provides metabolic effect beyond GLP-1 class (thermogenesis, hepatic fat oxidation)
Common issues (5)
  • Not FDA-approved; limited grey-market availability vs. tirzepatide or retatrutide
  • Severe GI burden: ~75% of Phase 2 participants reported GI side effects
  • 40-week titration schedule before reaching therapeutic doses: unusually slow ramp
  • Phase 3 weight loss at 6.0mg (9.8 to 13.0% at 76 weeks) looks smaller than Phase 2 headline figures, which used a different analysis
  • Non-linear dose-response: 6.0mg showed WORSE MASH improvement than 4.8mg in Phase 2
Science-Only Evidence

Community interest exists but meaningful self-reported dosing data is essentially absent. The compound is too difficult to source and the titration schedule too long for substantial grey-market use. All meaningful data is from controlled trials.

Survodutide Dosage Guide

Clinical TrialPhase 2 dose-finding trial: survodutide 0.6, 2.4, 3.6, and 4.8 mg weekly in adults with obesity (Lancet Diabetes Endocrinol 2024) (n=387)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner600 mcg
WeeklyTrack
Moderate2.4 mg
WeeklyTrack
Aggressive4.8 mg
WeeklyTrack
Note:

Survodutide requires a 10 mg vial and 2 mL bacteriostatic water for reconstitution. That gives you 5 mg/mL, or 5,000 mcg/mL. On a standard U-100 insulin syringe, each unit equals 50 mcg. So 0.6 mg (the starting dose) is 12 units. The 1.2 mg escalation dose is 24 units. At the full 4.8 mg MASH target, you're drawing 96 units.

The thing most people miss about survodutide is the escalation timeline. You're looking at 40 weeks of dose escalation before reaching therapeutic range. That's nearly 10 months. The clinical trials built this in deliberately because the GI burden is dose-dependent; skipping steps causes severe nausea and vomiting.

If you need to pause dosing for more than 2 weeks, restart from 0.6 mg and re-titrate. That's the clinical trial protocol, not optional caution. Store reconstituted vials at 2 to 8 degrees Celsius and use within 4 weeks.

Cycling

No scheduled off period.

Based on SYNCHRONIZE Phase 3 trial design (76 weeks). Titrate from 0.6mg weekly over 20 weeks. Long-term maintenance data not yet available.

Calculate your Survodutide dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Survodutide Protocols by Goal

advancedClinical Trial76 weeks (SYNCHRONIZE Phase 3 design)
Phase 1: Initial titration
Wk 1–8
600 mcg (0.6 mg) · Once weekly · Subcutaneous
Phase 2: Dose escalation 1
Wk 9–16
1,200 mcg (1.2 mg) · Once weekly · Subcutaneous
Phase 3: Dose escalation 2
Wk 17–24
1,800 mcg (1.8 mg) · Once weekly · Subcutaneous
Phase 4: Dose escalation 3
Wk 25–32
2,400 mcg (2.4 mg) · Once weekly · Subcutaneous
Phase 5: Dose escalation 4
Wk 33–40
3,600 mcg (3.6 mg) · Once weekly · Subcutaneous

Expected: Phase 2 at 4.8mg: 18.7% weight loss at 46 weeks (actual-treatment analysis; 14.9% planned-treatment mITT). 83% achieved ≥5% weight loss; 55% ≥15%. Phase 3 at 6.0mg: 13.0% at 76 weeks without diabetes (SYNCHRONIZE-1).

Monitor: Monitor weight, GI tolerability, blood glucose (T2D patients especially). Hepatic function panel at baseline and quarterly for MASH patients.

How to Inject Survodutide

  1. 1
    Step 1

    Reconstitute one 10 mg vial with 2.0 mL bacteriostatic water. Aim the stream at the glass wall, not directly onto the powder. Swirl gently until dissolved. This yields 5,000 mcg per mL (50 mcg per insulin syringe unit).

  2. 2
    Step 2

    Draw your dose using a U-100 insulin syringe with a 29 to 31 gauge needle. Starting dose: 12 units (600 mcg / 0.6 mg). Escalation schedule: 24 units at week 9 (1.2 mg), 36 units at week 17 (1.8 mg), 48 units at week 25 (2.4 mg), 72 units at week 33 (3.6 mg).

  3. 3
    Step 3

    At the 6.0 mg Phase 3 target dose, you'll need 120 units (a full 1 mL draw). Use a 1 mL syringe or split into two 0.5 mL draws from the same vial.

  4. 4
    Inject subcutaneously into the abdomen, thigh, or upper arm

    Rotate injection sites each week to prevent lipohypertrophy (the C18 diacid modification makes site rotation especially important).

  5. 5
    Pin on the same day each week

    If you're getting significant nausea during escalation, switch to evening injections before sleep. Pre-medicating with ondansetron during escalation weeks is a practical option if GI tolerance is consistently poor.

  6. 6
    Step 6

    Store reconstituted vials at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). Discard after 4 weeks.

Mixing your own vial? Use the Survodutide reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Survodutide Stacking Protocols

Works With

UDCA (Ursodiol)

Community-discussed adjunct for MASH. Hepatoprotective bile acid. Not clinically tested with survodutide. Theoretical additive hepatic benefit; limited to community speculation.

Avoid

Semaglutide

Do not combine: overlapping GLP-1 receptor agonism with additive GI toxicity and no additional mechanistic benefit.

Do not combine
Tirzepatide

Do not combine: overlapping GLP-1 receptor agonism with additive GI toxicity.

Do not combine
Retatrutide

Do not combine: overlapping GLP-1 and glucagon receptor agonism. Nearly identical mechanistic profile with additive GI toxicity and unpredictable combined pharmacodynamics.

Do not combine
Mazdutide

Do not combine: both are GLP-1/glucagon dual agonists with identical receptor overlap and additive GI toxicity.

Do not combine

Estimated Cost

Brand Price
Not commercially available. Investigational only as of October 2026. No NDA filing officially confirmed.

Pricing updated 2026-04-09

Survodutide Side Effects

Survodutide's dominant safety signal is gastrointestinal toxicity. In the Phase 2 obesity trial, approximately 75% of participants on survodutide reported gastrointestinal side effects. Nausea, diarrhea, and vomiting were the most common, and they followed a predictable pattern tied to dose escalation. Each step up in dose triggered a new wave of GI symptoms that typically settled within 2 to 4 weeks at a stable dose level.

The frequency data from Phase 2 breaks down as follows. Nausea was common (reported in more than 40% of participants at 4.8 mg). Diarrhea affected roughly 20 to 30%. Vomiting occurred in approximately 15 to 25% depending on the dose arm. Decreased appetite was frequent but often welcomed by participants in the obesity trial. Constipation showed up at higher doses as well.

One safety point that deserves attention: the GLP-1 receptor agonist class carries a boxed warning in approved compounds (semaglutide, tirzepatide) for thyroid C-cell tumors observed in rodent studies. This signal has not been confirmed in humans, but survodutide belongs to the same class. Thyroid monitoring at baseline is warranted.

Pancreatitis is a class concern. Any episode of persistent, severe abdominal pain should prompt lipase and amylase testing and immediate discontinuation if pancreatitis is confirmed.

For people with type 2 diabetes on insulin or sulfonylureas, adding survodutide raises hypoglycemia risk. The glucagon component partially offsets this in non-diabetic users, but the combination with exogenous insulin removes that safety margin.

Contraindications include personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), history of pancreatitis, pregnancy, breastfeeding, severe gastrointestinal disease such as gastroparesis, and decompensated cirrhosis. A dedicated pharmacokinetic study [3] confirmed that survodutide's PK is not significantly altered by cirrhosis, but safety data in decompensated (Child-Pugh C) cirrhosis is insufficient.

If GI effects are disproportionately severe at the 0.6 mg starting dose, suspect inaccurate vial concentration from grey-market sourcing. A certificate of analysis is the only way to check the batch.

Common Issues & Solutions

Nausea peaks at each dose escalation step: reduce escalation pace (extend current dose by 4 additional weeks) rather than stopping. Most GI effects resolve within 2–4 weeks at a stable dose.

Phase 2 showed 6.0mg had WORSE MASH improvement than 4.8mg (43% vs 62%): for liver endpoints specifically, higher dose is not better. Target 4.8mg for MASH, not 6.0mg.

Vomiting during titration: switch injection to evening before sleep. Pre-medicate with ondansetron for escalation weeks if GI tolerance is consistently poor.

If dosing is interrupted >2 weeks, restart from 0.6mg and re-titrate: matches clinical trial protocol and minimizes rebound GI effects.

Grey-market purity variance: if GI effects are disproportionately severe at low doses (0.6mg), suspect overdose from inaccurate concentration. Only a CoA can confirm the batch; consider reconstituting with more BAC water.

Ask AI about this page

Ask AI for a second opinion on Survodutide dosing and side effects

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • History of pancreatitis or active pancreatitis
  • Pregnancy or planning to become pregnant
  • Breastfeeding
  • Known hypersensitivity to survodutide or any excipients
  • Severe gastrointestinal disease (e.g., gastroparesis)
  • Decompensated cirrhosis (limited safety data available)

Drug Interactions

  • Insulin and sulfonylureas: increased hypoglycemia risk; dose reduction often needed
  • Other GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide): do not combine; overlapping mechanism
  • Oral contraceptives: reduced efficacy due to delayed gastric emptying; use barrier method during titration
  • Oral medications with narrow therapeutic index (e.g., warfarin): monitor closely due to delayed gastric emptying
  • Anticholinergic drugs: may compound GI side effects and further slow gastric motility
  • Do not combine: overlapping GLP-1 receptor agonism with additive GI toxicity and no additional mechanistic benefit.
  • Do not combine: overlapping GLP-1 receptor agonism with additive GI toxicity.
  • Do not combine: overlapping GLP-1 and glucagon receptor agonism. Nearly identical mechanistic profile with additive GI toxicity and unpredictable combined pharmacodynamics.
  • Do not combine: both are GLP-1/glucagon dual agonists with identical receptor overlap and additive GI toxicity.

Product Quality

Recommended Monitoring

TestWhenTarget
Body weightWeeklyNot listed
Liver function panel (ALT, AST, bilirubin, INR, albumin)Baseline, then every 12 weeksALT/AST trending toward normal; INR <1.5; albumin >3.5 g/dL
MRI-PDFF or liver ultrasoundBaseline and 48 weeksNot listed
Fasting glucose and HbA1cBaseline, week 12, week 24, then every 24 weeksFasting glucose 70–100 mg/dL (non-T2D); HbA1c per T2D treatment goals
TSH (thyroid)Baseline; annually or if symptoms ariseNot listed
Lipase / amylaseAt any episode of persistent abdominal painNot listed
Body weight

Primary efficacy measure; track 5% and 10% milestone thresholds

Liver function panel (ALT, AST, bilirubin, INR, albumin)

MASH patients: confirm hepatic benefit vs. worsening. Flag decompensation early.

MRI-PDFF or liver ultrasound

Objective liver fat quantification: key MASH endpoint used in Phase 2 trial.

Fasting glucose and HbA1c

Glucagon receptor agonism can cause transient glucose fluctuation; T2D patients require closer monitoring during escalation.

TSH (thyroid)

Class precaution for GLP-1 receptor agonists: rodent thyroid C-cell signal not confirmed in humans but warrants baseline.

Lipase / amylase

Rule out pancreatitis: class risk for GLP-1 agonists

Survodutide Before and After

Weeks 1-4

Starting dose 0.6mg weekly. Mild appetite suppression may begin. GI side effects (nausea, diarrhea) are most common during early titration. Minimal weight loss expected: this is a tolerability phase.

Weeks 5-12

Dose escalated through 1.2mg and 1.8mg. Appetite reduction becomes more noticeable. Early weight loss of 2-4%. GI symptoms typically peak during each dose increase then improve.

Weeks 13-20

Continued escalation toward target dose (3.6mg or 6.0mg). Steady weight loss accumulating. Liver fat reduction measurable on imaging in MASH patients.

Weeks 21-46

Maintenance at target dose. Phase 2 data showed up to 14.9% weight loss at 46 weeks (4.8mg, planned treatment analysis) and nearly 19% in completers. MASH trial showed 62% improved in MASH without worsening fibrosis at 48 weeks.

Weeks 47-76

Extended maintenance phase (Phase 3 SYNCHRONIZE design). Further weight loss and metabolic improvements expected. Long-term outcomes data pending from ongoing trials.

What to Expect

Weeks 1 through 8: Starting dose is 0.6 mg weekly. Expect minimal weight change during this phase. GI adaptation is the priority, not results. Nausea and diarrhea are most likely during these first weeks. No meaningful liver fat reduction occurs yet. No substantive community dosing data exists for this compound.

Weeks 9 through 24: Dose climbs through 1.2 mg and 1.8 mg with escalation every 4 to 8 weeks. Appetite suppression kicks in noticeably. Early weight loss of 2 to 5% may start. GI symptoms peak around each dose step, then settle within 2 to 4 weeks. Nausea, vomiting, and constipation are the main complaints during this window.

Weeks 25 through 40: Mid-range doses of 2.4 to 3.6 mg. Cumulative weight loss reaches 5 to 10%. For MASH patients, liver fat reduction becomes measurable on imaging. The 3.6 mg level is the Phase 3 SYNCHRONIZE low-dose arm target.

Weeks 41 through 48: Therapeutic dose of 4.8 mg. Phase 2 obesity data at this level: 14.9% weight loss at 46 weeks (modified intention-to-treat). The MASH trial showed 62% of participants improved in MASH without worsening of fibrosis at 48 weeks, and 67% had at least a 30% liver fat reduction. GI effects typically stabilize once the dose holds steady.

Weeks 49 through 76: Extended maintenance matching the Phase 3 SYNCHRONIZE design. Weight loss may continue or plateau. Long-term outcomes data is pending from ongoing trials.

Detailed Timeline: Science vs Community

Weeks 1–8
Science

Minimal weight change. GI adaptation at 0.6mg. No significant liver fat reduction yet.

Community

No substantive first-person data available.

Weeks 9–24
Science

Early appetite suppression begins. Weight loss of 2–5% may start. GI symptoms peak around each dose step, then improve.

Community

No first-person data. Clinical data: GI effects peak and resolve within 2–4 weeks per dose level.

Weeks 25–40
Science

Cumulative weight loss 5–10%. Liver fat reduction measurable on imaging for MASH patients.

Community

No first-person data.

Weeks 41–48
Science

Phase 2 obesity: 14.9% weight loss at 46 weeks (mITT). MASH trial: 62% improved in MASH without worsening of fibrosis and 67% with at least a 30% liver fat reduction at 48 weeks.

Community

No first-person data.

Weeks 49–76
Science

Phase 3 SYNCHRONIZE ran 76 weeks: 12.2 to 13.0% weight loss without diabetes and 8.2 to 9.8% with type 2 diabetes (treatment-regimen estimand).

Community

No data available.

Pharmacokinetics

Half-Life
144h
Bioavailability
SC: ~80-90% (preclinical)
Tmax
2-3 days
Data Confidence
moderate

Source: Phase 1/2 PK data; t½ ~109-115h median, ~6 days reported (albumin-bound C18 diacid conjugate)

Pharmacokinetics: Active Dose Over Time

t½ = ~6 days

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
29
Molecular Weight
4,231.63 Da
Sequence
HXQGTFTSDYSKYLDERAAKDFIKWLESA
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 2805997-46-8

Who Should Consider Survodutide

  • Adults with BMI ≥30 (or ≥27 with weight-related comorbidity)
  • Patients with MASH/NASH and liver fibrosis (F1-F3)
  • Adults with obesity and type 2 diabetes (SYNCHRONIZE-2 population)
  • Patients who have not responded adequately to GLP-1-only agonists
  • Adults with obesity-related cardiovascular risk factors

Related Peptides

What Changed for Survodutide

  1. Evidence

    SYNCHRONIZE-2 found 9.8% weight loss on survodutide 6.0 mg vs 3.9% on placebo at 76 weeks in type 2 diabetes, published Oct 1, 2026, per NEJM.

    What this does not mean: A weight trial in obesity with type 2 diabetes (NCT06066528), not a MASH trial. Survodutide has no FDA approval.

    Source: N Engl J Med 2026, Survodutide once weekly in adults with obesity and type 2 diabetes (SYNCHRONIZE-2) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Dates to watch

  1. Trial primary completion, estimated

    LIVERAGE, a Phase 3 trial of survodutide in MASH with moderate or advanced fibrosis, has an estimated primary completion date, per ClinicalTrials.gov.

    What this does not mean: Primary completion is when the last participant gives data for the main outcome, not when results come out. Estimated dates often move.

Peptide Schedule Research TeamReviewed Aug 7, 20268 Citations

References

  1. [1]A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (NEJM) (opens in a new tab)(n=293)PubMed (opens in a new tab)PubMed
  2. [2]Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a phase 2 dose-finding trial (opens in a new tab)(n=387)PubMed (opens in a new tab)PubMed
  3. [3]Efficacy, tolerability and pharmacokinetics of survodutide in cirrhosis (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]SYNCHRONIZE-1: Survodutide Once Weekly for the Treatment of Adults with Obesity: SYNCHRONIZE-1 Phase 3 (NEJM 2026) (opens in a new tab)(n=725)PubMed (opens in a new tab)PubMed
  5. [5]SYNCHRONIZE-2: Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes: SYNCHRONIZE-2 Phase 3 (NEJM 2026) (opens in a new tab)(n=752)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C
After Reconstitution
Refrigerate at 2-8°C, use within 4 weeks
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

The glucagon receptor component directly drives hepatic fat oxidation: something GLP-1-only drugs can't do on their own. In the Phase 2 MASH trial, survodutide 4.8 mg improved MASH without worsening fibrosis in 62% of participants, versus 14% on placebo. Semaglutide's liver fat effects are largely a side benefit of weight loss.

Weight loss hadn't plateaued at 46 weeks with 4.8 mg in the Phase 2 obesity trial. Boehringer Ingelheim selected 6.0 mg for Phase 3 to see if they can push efficacy further. In SYNCHRONIZE-1, 6.0 mg produced 13.0% weight loss at 76 weeks vs 12.2% on 3.6 mg and 5.4% on placebo (NEJM 2026, PMID 42253238).

No: therapeutic glucagon receptor agonism at these doses primarily increases hepatic fat oxidation and energy expenditure, not blood glucose. The GLP-1 component provides a glucose-lowering counterbalance. Clinical trials showed no significant hypoglycemia in non-diabetic participants.

It depends on the goal. For weight, Phase 3 tested 3.6 mg and 6.0 mg over 76 weeks. People without diabetes lost 12.2% and 13.0% vs 5.4% on placebo (SYNCHRONIZE-1). People with type 2 diabetes lost 8.2% and 9.8% vs 3.9% (SYNCHRONIZE-2). For MASH, 4.8 mg still has the best biopsy data: 62% improved without worsening fibrosis in Phase 2. The MASH Phase 3, LIVERAGE, hasn't reported yet.

Survodutide's pharmacokinetics aren't significantly changed by cirrhosis (confirmed by a dedicated PK study). But safety data in decompensated cirrhosis (meaning Child-Pugh C with ascites, encephalopathy) is insufficient. The drug may be appropriate in compensated cirrhosis with monitoring, but is off-limits when liver function is severely compromised.